MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414995 | Name: Piridoxilate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Piridoxilate is a conjugation product of glyoxylic acid & pyridoxine; may be physiological regulator of cell respiration. It has been shown that long-term treatment with piridoxilate may result in overproduction of oxalic acid and in calcium oxalate nephrolithiasis.

Chemical Structure

Piridoxilate
Piridoxilate
CAS#24340-35-0

Theoretical Analysis

MedKoo Cat#: 414995

Name: Piridoxilate

CAS#: 24340-35-0

Chemical Formula: C20H26N2O12

Exact Mass: 486.1486

Molecular Weight: 486.43

Elemental Analysis: C, 49.38; H, 5.39; N, 5.76; O, 39.47

Price and Availability

Size Price Availability Quantity
50mg USD 410.00 2 Weeks
250mg USD 935.00 2 Weeks
500mg USD 1,605.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Piridoxilate; Piridoxilato; Piridoxilatum
IUPAC/Chemical Name
((5-Hydroxy-4-(hydroxymethyl)-6-methyl-3-pyridyl)methoxy)glycolic acid compound with ((4,5-bis(hydroxymethyl)-2-methyl-3-pyridyl)oxy)glycolic acid (1:1)
InChi Key
TWVSQBMULZSRIJ-UHFFFAOYSA-N
InChi Code
InChI=1S/2C10H13NO6/c1-5-8(13)7(3-12)6(2-11-5)4-17-10(16)9(14)15;1-5-8(17-10(16)9(14)15)7(4-13)6(3-12)2-11-5/h2*2,10,12-13,16H,3-4H2,1H3,(H,14,15)
SMILES Code
OC(OCC1=C(CO)C(O)=C(C)N=C1)C(O)=O.OC(OC2=C(CO)C(CO)=CN=C2C)C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 486.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mousson C, Justrabo E, Rifle G, Sgro C, Chalopin JM, Gérard C. Piridoxilate- induced oxalate nephropathy can lead to end-stage renal failure. Nephron. 1993;63(1):104-6. doi: 10.1159/000187151. PMID: 8446234. 2: Lantos J, Temes G, Kelemen D, Sárosi I, Török B Jr. Influence of protective drugs on the elevation of extracellular potassium ion concentration in the brain during ischaemia. Acta Physiol Hung. 1990;76(1):49-59. PMID: 2088011. 3: Cyr DM, Tremblay GC. On combination therapy with benzoate and piridoxilate. Am J Dis Child. 1989 Dec;143(12):1392. doi: 10.1001/archpedi.1989.02150240014006. PMID: 2589268. 4: Normand M, Bergua D, Bouvet JP, Cayotte JL, Gottis M. Corrélations entre la cause et la composition des calculs rénaux Intérêt d'une analyse morphologique et infrarouge [Correlation of the cause and composition of renal calculi. Value of morphologic and infrared analysis]. Ann Biol Clin (Paris). 1989;47(1):29-34. French. PMID: 2648901. 5: Daudon M, Reveillaud RJ, Normand M, Petit C, Jungers P. Piridoxilate-induced calcium oxalate calculi: a new drug-induced metabolic nephrolithiasis. J Urol. 1987 Aug;138(2):258-61. doi: 10.1016/s0022-5347(17)43111-9. PMID: 3599232. 6: Vigeral P, Kenouch S, Chauveau D, Mougenot B, Méry JP. Piridoxilate- associated nephrocalcinosis: a new form of chronic oxalate nephropathy. Nephrol Dial Transplant. 1987;2(4):275-8. PMID: 3118272. 7: Daudon M, Reveillaud RJ, Jungers P. Piridoxilate-associated calcium oxalate urinary calculi: a new metabolic drug-induced nephrolithiasis. Lancet. 1985 Jun 8;1(8441):1338. doi: 10.1016/s0140-6736(85)92835-1. PMID: 2860529. 8: Daudon M, Reveilland RJ, Jungers P. Calculs récidivants d'oxalate de calcium chez nes malades traités par le piridoxilate [Recurrent calcium oxalate calculi in patients treated with piridoxylate]. Presse Med. 1985 Apr 13;14(15):846-7. French. PMID: 3158917. 9: Dequiedt P, Gosselin B, Benoit O, Le Maguer D, Lebleu J, MacNamara E, Pagniez D, Dracon M, Lelièvre G, Tacquet A. Insuffisance rénale aiguë par oxalose aiguë après ingestion massive de piridoxilate [Acute renal failure caused by acute oxalosis after massive ingestion of pyridoxilate]. Nephrologie. 1985;6(5):228-30. French. PMID: 4094637. 10: Wolf C, Maistre-Charransol G, Barthelemy C, Ottavioli JN, Thomas E, Thomas J. Lithiase oxalique iatrogène par le piridoxilate [Iatrogenic oxalic lithiasis caused by pyridoxilate]. Nephrologie. 1985;6(5):225-7. French. PMID: 4094636. 11: Wolf C, Maistre-Charransol G, Barthélémy C, Thomas E, Thomas J, Arvis G, Steg A. Lithiase oxalocalcique et hyperoxalurie secondaires à un traitement par le piridoxilate [Calcium oxalate stones and hyperoxaluria secondary to treatment with pyridoxilate]. Ann Urol (Paris). 1985;19(5):313-7. French. PMID: 4083839. 12: Saletu B, Grünberger J. Memory dysfunction and vigilance: neurophysiological and psychopharmacological aspects. Ann N Y Acad Sci. 1985;444:406-27. doi: 10.1111/j.1749-6632.1985.tb37604.x. PMID: 3860093. 13: Wolf C, Maistre-Charransol G, Barthelemy C, Thomas E, Thomas J. Lithiase oxalique médicamenteuse par le piridoxilate [Drug-induced oxalic lithiasis from pyridoxilate]. Presse Med. 1984 Dec 8;13(44):2703. French. PMID: 6240037. 14: Saletu B, Grünberger J, Lesch O. Zum Einfluss von Nootropika auf den normalen und gestörten Schlaf des älteren Menschen: Kontrollierte Studien mit Piridoxilat und Strassenlärm [Effect of nootropic drugs on normal and disturbed sleep of the elderly: controlled studies with pyridoxilate and street noise]. Wien Klin Wochenschr. 1984 Nov 23;96(22):817-22. German. PMID: 6396969. 15: Coude FX, Coude M, Grimber G, Pelet A, Charpentier C. Potentiation by piridoxilate of the synthesis of hippurate from benzoate in isolated rat hepatocytes. An approach to the determination of new pathways of nitrogen excretion in inborn errors of urea synthesis. Clin Chim Acta. 1984 Jan 31;136(2-3):211-7. doi: 10.1016/0009-8981(84)90294-8. PMID: 6692575. 16: Saletu B, Saletu M, Grünberger J, Mader R. Spontaneous and drug-induced remission of alcoholic organic brain syndrome: clinical, psychometric, and neurophysiological studies. Psychiatry Res. 1983 Sep;10(1):59-75. doi: 10.1016/0165-1781(83)90028-8. PMID: 6580659. 17: Rumeau M, Pourrat J, Chambeu Y. Effets de l'association PETN-piridoxilate dans le traitement au long cours de l'insuffisance cardiaque du sujet âgé [Effects of the PETN-piridoxylate combination in the long-term treatment of cardiac failure in the aged patient]. Sem Hop. 1983 May 12;59(19):1475-8. French. PMID: 6310765. 18: Baudet M, Hericotte P. Recherche d'un effet hémodynamique prolongé du pentaérithrityle tétranitrate associe au piridoxilate [Prolonged hemodynamic effects of pentaerythrityl tetranitrate combined with piridoxylate]. Sem Hop. 1983 Mar 10;59(10):683-5. French. PMID: 6304889. 19: Otorii T, Katano Y, Takeda K, Imai S. Effects of piridoxilate, a glyoxylic acid derivative, on the energy metabolism of the heart. Jpn Heart J. 1980 Nov;21(6):845-57. doi: 10.1536/ihj.21.845. PMID: 7463722. 20: Fischer JH. Der Einfluss von Piridoxilat aud den Energiesstoffwechsel normotherm ischämischer Organe der Ratte [Influence of piridoxilate on the energy metabolism of normothermic ischemic organs in the rat]. Arzneimittelforschung. 1980;30(12):2132-4. German. PMID: 7194075.